Genmab A/S
GNMSF
Get informed when a big investor buys or sells
+ FollowMarket Cap$150.11B
Close$
Share Statistics
| Market cap | $150.11 Billion |
|---|---|
| Enterprise Value | $153.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $16.04 |
| Beta | 0.69 |
| Outstanding Shares | 61,336,032 |
Return
| Return on Equity | 16.02% |
|---|---|
| Return on Assets | 7.62% |
| Return on Invested Capital | 23.38% |
Valuation & Multiples
| P/E Ratio | 28.63 |
|---|---|
| PEG | -291.48 |
| Price to Sales | 2.31 |
| Price to Book Ratio | 3.78 |
| Enterprise Value to Revenue | 15.71 |
| Enterprise Value to EBIT | 57.86 |
| Enterprise Value to Net Income | 161 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.89 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$3.56
Average shareholder expectationRevenue Estimate
$1.12 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$3.45
Average shareholder expectationRevenue Estimate
$1.20 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genmab
3,029 employees
CEO: Jan van de Winkel Genmab A/S, established in 1999 and headquartered in Copenhagen, Denmark, is a biotechnology firm specializing in the development of antibody therapeutics for cancer and various other medical conditions, primarily operating from its Dani...